Mannan-modified adenovirus targeting TERT and VEGFR-2: A universal tumour vaccine

Scientific Reports

Volumn 5, Issue , 2015, Pages

  Wang, Ying ^a,b   Zhang, Jie ^a   Wu, Yang ^a   Ding, Zhen Yu ^a   Luo, Xin Mei ^a   Liu, Jie ^a   Zhong, Wu Ning ^a   Deng, Guo Hua ^a   Xia, Xiang Yu ^a   Deng, Yao Tiao ^a   Wei, Yu Quan ^a   Jiang, Yu ^a  

^a SICHUAN UNIVERSITY   (China)

^b SICHUAN PROVINCIAL PEOPLE'S HOSPITAL   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER VACCINE; CYTOKINE; LECTIN RECEPTOR; MANNAN; MANNAN RECEPTOR; TELOMERASE; VASCULOTROPIN RECEPTOR 2;

ADENOVIRIDAE; ADMINISTRATION AND DOSAGE; ANIMAL; BIOSYNTHESIS; CYTOLOGY; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; DISEASE MODEL; FEMALE; GENE EXPRESSION; GENE VECTOR; GENETICS; HUMAN; IMMUNIZATION; IMMUNOLOGY; IMMUNOTHERAPY; LYMPHOCYTE COUNT; METABOLISM; MOUSE; NEOPLASMS; NEOVASCULARIZATION (PATHOLOGY); PROCEDURES; REPORTER GENE; SPLEEN; T LYMPHOCYTE SUBPOPULATION; TUMOR ASSOCIATED LEUKOCYTE;

ADENOVIRIDAE; ANIMALS; CANCER VACCINES; CYTOKINES; DENDRITIC CELLS; DISEASE MODELS, ANIMAL; FEMALE; GENE EXPRESSION; GENES, REPORTER; GENETIC VECTORS; HUMANS; IMMUNIZATION; IMMUNOTHERAPY; LYMPHOCYTE COUNT; LYMPHOCYTES, TUMOR-INFILTRATING; MANNANS; MICE; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; RECEPTORS, MITOGEN; SPLEEN; T-LYMPHOCYTE SUBSETS; T-LYMPHOCYTES, CYTOTOXIC; TELOMERASE; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 84934988003     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep11275     Document Type: Article

References (61)

1. Risau, W. Mechanisms of angiogenesis. Nature. 386, 671-4 (1997).
2. Gaspariru, G. The rationale and future potential of angiogenesis inhibitors in neoplasia. Drugs. 58, 17-38 (1999).
3. Vajkoczy, P. et al. Microtumor growth initiates angiogenic sprouting with simultaneous expression of VEGF, VEGF receptor-2, and angiopoietin-2. J Clin Invest. 109, 777-85 (2002).
4. McMahon, G. VEGF receptor signaling in tumor angiogenesis. Oncologis. 5, 3-10 (2000).
5. Gille, H. et al. Analysis of biological effects and signaling properties of Flt-1 (VEGFR-1) and KDR (VEGFR-2). J Biol Chem 276, 3222-30 (2001).
6. Wang, B., Kaumaya, P. T. & Cohn, D. E. Immunization with synthetic VEGF peptides in ovarian cancer. Gynecol Oncol. 119, 564-70 (2010).
7. Morera, Y. et al. Anti-tumoral effect of active immunotherapy in C57BL/6 mice using a recombinant human VEGF protein as antigen and three chemically unrelated adjuvants. Angiogenesis. 11, 381-93 (2008).
8. Dong, J. et al. A comparative study of gene vaccines encoding different extracellular domains of the vascular endothelial growth factor receptor 2 in the mouse model of colon adenocarcinoma CT-26. Cancer Biol Ther. 7, 502-9 (2008).
9. Zhang, H. et al. Antiangiogenic immunotherapy targeting Flk-1, DNA vaccine and adoptive T cell transfer, inhibits ocular neovascularization. Biochem Biophys Res Commun. 381, 471-476 (2009).
10. Bequet-Romero, M. et al. Prophylactic naked DNA vaccination with the human vascular endothelial growth factor induces an anti-tumor response in C57Bl/6 mice. Angiogenesis. 10, 23-34 (2007).
11. Wei, Y. et al. Enhancement of DNA vaccine efficacy by targeting the xenogeneic human chorionic gonadotropin, survivin and vascular endothelial growth factor receptor 2 combined tumor antigen to the major histocompatibility complex class II pathway. J Gene Med. 14, 353-62 (2012).
12. Luo, Y., Markowitz, D., Xiang, R., Zhou, H. & Reisfeld, R. A. FLK-1-based minigene vaccines induce T cell-mediated suppression of angiogenesis and tumor protective immunity in syngeneic BALB/c mice. Vaccine. 25, 1409-15 (2007).
13. Hurwitz, H. et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 350, 2335-42 (2004).
14. Escudier, B. et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma:a randomised, doubleblind phase III trial. Lancet. 370, 2103-11 (2007).
15. Sandler, A. et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med. 355, 2542-50 (2006).
16. Ma, J. & Waxman, D. J. Dominant effect of antiangiogenesis in combination therapy involving cyclophosphamide and axitinib. Clin Cancer Res. 15, 578-88 (2009).
17. Blagosklonny, M. V. Antiangiogenic therapy and tumor progression. Cancer Cell 5, 13-7 (2004).
18. Hall, S. S. A Commotion in the Blood: Life, Death, and the Immune System. [Hall, S. S. (ed.)] (New York, 1997).
19. Sylvester, R. J. Bacillus Calmette-Guerin treatment of non-muscle invasive bladder cancer. Int J Urol. 18, 113-20 (2011).
20. Nair, S. et al. Synergy between tumor immunotherapy and antiangiogenic therapy. Blood 102, 964-71 (2003).
21. Kim, N. W. et al. Specific association of human telomerase activity with immortal cells and cancer. Science. 266, 2011-5 (1994).
22. Meyerson, M. et al. hEST, the putative human telomerase catalytic subunit gene, is up-regulated in tumor cells and during immortalization. Cell. 90, 785-95 (1997).
23. Vonderheide, R. H. Telomerase as a universal tumor-associated antigen for cancer immunotherapy. Oncogene. 21, 674-679 (2002).
24. East, L. & Isacke, C. M. The mannose receptor family. Biochim Biophys Acta. 1572, 364-86 (2002).
25. Irjala, H. et al. Mannose receptor is a novel ligand for L-selectin and mediates lymphocyte binding to lymphatic endothelium. J Exp Med. 194, 1033-42 (2001).
26. Condaminet, B. et al. Human epidermal Langerhans cells express the mannose-fucose binding receptor. Eur J Immunol. 28, 3541-51 (1998).
27. Apostolopoulos, V., Pietersz, G. A., Loveland, B. E., Sandrin, M. S. & McKenzie, I. F. Oxidative/reductive conjugation of mannan to antigen selects for T1 or T2 immune responses. Proc Natl Acad Sci U S A. 92, 10128-32 (1995).
28. Ding, Z. et al. Mannan-modified adenovirus as a vaccine to induce antitumor immunity. Gene Ther. 14, 657-63 (2007).
29. Zhao, Z. et al. Antitumour immunity mediated by mannan-modified adenovirus vectors expressing VE-cadherin. Vaccine 29, 4218-24(2011).
30. Kamphorst, A. O. et al. Route of antigen uptake differentially impacts presentation by dendritic cells and activated monocytes. J Immunol. 185, 3426-35 (2010).
31. Céspedes, M. V., Casanova, I., Parreño, M. & Mangues, R. Mouse models in oncogenesis and cancer therapy. Clin Transl Oncol. 8, 318-29 (2006).
32. Ruggeri, B. A., Camp, F. & Miknyoczki, S. Animal models of disease: pre-clinical animal models of cancer and their applications and utility in drug discovery. Biochem Pharmacol. 87, 150-61 (2014).
33. Jung, J. Human tumor xenograft models for preclinical assessment of anticancer drug development. Toxicol Res. 30, 1-5 (2014).
34. Richmond, A. & Su, Y. Mouse xenograft models vs GEM models for human cancer therapeutics. Dis Model Mech. 1, 78-82 (2008).
35. Terme, M. et al. VEGFA-VEGFR pathway blockade inhibits tumor-induced regulatory T-cell proliferation in colorectal cancer. Cancer Res. 73, 539-49 (2013).
36. Tartour, E. et al. Angiogenesis and immunity: a bidirectional link potentially relevant for the monitoring of antiangiogenic therapy and the development of novel therapeutic combination with immunotherapy. Cancer Metastasis Rev. 30, 83-95 (2011).
37. Kochenderfer, J. N. & Gress, R. E. A comparison and critical analysis of preclinical anticancer vaccination strategies. Exp Biol Med (Maywood). 232, 1130-41 (2007).
38. Murali-Krishna, K. et al. Counting antigen-specific CD8 T cells: a reevaluation of bystander activation during viral infection. Immunity. 8, 177-87 (1998).
39. Gattinoni, L. et al. CTLA-4 dysregulation of self/tumor-reactive CD8+ T-cell function is CD4+ T-cell dependent. Blood. 108, 3818-23 (2006).
40. Wang, R. F. The role of MHC class II-restricted tumor antigens and CD4+ T cells in antitumor immunity. Trends Immunol. 22, 269-76 (2001).
41. Shedlock, D. J. & Shen, H. Requirement for CD4 T cell help in generating functional CD8 T cell memory. Science. 300, 337-9 (2003).
42. Ostrand-Rosenberg, S. CD4+ T lymphocytes: a critical component ofantitumor immunity. Cancer Invest. 23, 413-9 (2005).
43. Lau, B. H., Yamasaki, T. & Gridley, D. S. Garlic compounds modulate macrophage and T-lymphocyte functions. Mol Biother. 3, 103-7 (1991).
44. Ebrahimi, M., Mohammad Hassan, Z., Mostafaie, A., Zare Mehrjardi, N. & Ghazanfari, T. Purif ied Protein Fraction of Garlic Extract Modulates Cellular Immune Response against Breast Transplanted Tumors in BALB/c Mice Model. Cell J. 15, 65-75 (2013).
45. Galon, J. et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science. 313, 1960-4 (2006).
46. Seo, A. N. et al. Tumour-infiltrating CD8+ lymphocytes as an independent predictive factor for pathological complete response to primary systemic therapy in breast cancer. Br J Cancer. 109, 2705-13 (2013).
47. Prado-Garcia, H., Romero-Garcia, S., Aguilar-Cazares, D., Meneses-Flores, M. & Lopez-Gonzalez, J. S. Tumor-induced CD8+ T-cell dysfunction in lung cancer patients. Clin Dev Immunol 2012, 741741 (2012).
48. Gajewski, T. F. et al. Cancer immunotherapy strategies based on overcoming barriers within the tumor microenvironment. Curr Opin Immunol. 25, 268-276 (2013).
49. Cheroutre, H. & Husain, M. M. CD4 CTL: Living up to the challenge. Semin Immunol. 25, 273-81 (2013).
50. Qin, Z. et al. A critical requirement of interferon gamma-mediated angiostasis for tumor rejection by CD8+ T cells. Cancer Res. 63, 4095-100 (2003).
51. Beatty, G. & Paterson, Y. IFN-gamma-dependent inhibition of tumor angiogenesis by tumor-infiltrating CD4+ T cells requires tumor responsiveness to IFN-gamma. J Immunol. 166, 2276-82 (2001).
52. Schultz, R. M. & Kleinschmidt, W. J. Functional identity between murine gamma interferon and macrophage activating factor. Nature. 305, 239-40 (1983).
53. Pace, J. L., Russell, S. W., Torres, B. A., Johnson, H. M. & Gray, P. W. Recombinant mouse gamma interferon induces the priming step in macrophage activation for tumor cell killing. J Immunol. 130, 2011-3 (1983).
54. Zhang, L. et al. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med. 348, 203-13 (2003).
55. Zhang, J. et al. Mannan-modified adenovirus encoding VEGFR-2 as a vaccine to induce anti-tumor immunity. J Cancer Res Clin Oncol 140, 701-12 (2014).
56. Stambas, J., Pietersz, G., McKenzie, I. & Cheers, C. Oxidized mannan as a novel adjuvant inducing mucosal IgA production. Vaccine. 20, 1068-78 (2002).
57. Sauter, B. V., Martinet, O., Zhang, W. J., Mandeli, J. & Woo, S. L. Adenovirus-mediated gene transfer of endostatin in vivo results in a high level of transgene expression and inhibition of tumor growth and metastases. Proc Natl Acad Sci U S A. 97, 4802-7 (2000).
58. Lozonschi, L. et al. Controlling tumor angiogenesis and metastasis of C26 murine colon adenocarcinoma by a new matrix metalloproteinase inhibitor, KB-R7785, in two tumor models. Cancer Res. 59, 1252-8 (1999).
59. Blezinger, P. et al. Systemic inhibition of tumor growth and tumor metastases by intramuscular administration of the endostatin gene. Nat Biotechnol. 17, 343-8 (1999).
60. Niethammer, A. G. et al. A DNA vaccine against VEGF receptor 2 prevents effective angiogenesis and inhibits tumor growth. Nat Med. 8, 1369-75 (2002).
61. Chou, T. C. Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol Rev 58, 621-81 (2006).